« Back
Home /
Voxelotor

Voxelotor

Item no.	HY-18681-100mg
Manufacturer	MedChem Express
CASRN	1446321-46-5
Amount	100 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 200 mg 25 mg 500 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.99
Citations	[1]Oksenberg D, et al. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease. Br J Haematol. 2016 Oct;175(1):141-53.\|[2]Metcalf B, Chuang C, Dufu K, et al. Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin. ACS Med Chem Lett. 2017;8(3):321-326.
Smiles	OC1=CC=CC(OCC2=C(C3=CC=NN3C(C)C)N=CC=C2)=C1C=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	GBT 440
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Targets	Others
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, stored under nitrogen)
Molecular Weight	337.37
Product Description	Voxelotor (GBT 440) is a potent inhibitor of haemoglobin S (HbS) polymerization. Voxelotor has the potential for sickle cell disease (SCD) treatment[1].
Manufacturer - Research Area	Cardiovascular Disease
Solubility	DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Others
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-18681-100mg-safety-datasheet.pdf